INDV

Over the past six months, Indivior reported strong first-quarter 2026 financial results on April 30, 2026, leading to a 7.70% stock price increase, and announced it would not pursue Phase 3 development for INDV-6001 while evaluating INDV-2000. In June 2026, the company participated in the Jefferies Global Healthcare Conference and the Goldman Sachs 47th Annual Global Healthcare Conference. On August 3, 2026, Indivior's stock declined by 6.60% after reporting second-quarter 2026 financial results and announcing a proposed all-stock merger of equals with Supernus Pharmaceuticals, Inc., expected to close in Q4 2026, which included a conditional special cash dividend of $8.13 per share. From August to September 2026, several investor-rights firms initiated investigations into the fairness of the proposed merger to Indivior shareholders. On September 17, 2026, Indivior declared a special cash dividend. SEC filings on October 6, 2026, provided further details on a $1 billion special dividend related to the merger. In June 2026, there was insider selling by Christian Heidbreder and Ryan Preblick. As of September 26, 2026, the stock price had increased by 49.75% over the last 12 months, and by October 9, 2026, it had seen a 23.5% increase over the last six months.